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ABSTRACT
Viral nucleoprotein (NP) is an abundant essential protein of an influenza virus that has important functional and structural roles. 
It participates in genomic organization, nuclear trafficking, RNA transcription, and genome replication. From the research point 
of view, NP is an important protein that is used in the development of new diagnostic methods and vaccination protocols. NP is 
a promising target for antiviral chemotherapeutic drugs as well. Successful expression of codon-optimized NP genes in E. coli has 
been reported. In this study, we demonstrated the efficient expression and purification of soluble NPs of influenza A and B viruses 
in E. coli without the codon-optimization of DNA sequences. This procedure preserves the co-translational protein folding, pro-
tein configuration and function. Obtained NPs of influenza A and B viruses were monomers and reacted well with mouse specific 
antibodies according to Western blot analysis. Our results show that both influenza A and influenza B virus NPs can be efficiently 
expressed in E. coli without codon-optimization.
INTRODUCTION
Influenza viruses cause respiratory infections in hu-
mans that range from asymptomatic to deadly disease. 
Regular epidemics and pandemics make the influenza 
virus a global health threat. The nucleoprotein (NP) is a 
multifunctional viral protein with important structural 
and functional roles [1, 2]. It plays a critical role in viral 
replication. NP is involved in important functions such 
as RNA packaging [3], nuclear trafficking, transcription, 
and replication of vRNA [4, 5]. Each genomic segment of 
the influenza virus vRNA is associated with multiple NP 
molecules and a single polymerase complex (with PB2, 
PB1, and PA proteins) forming a viral ribonucleoprotein 
(vRNP) complex. The NP binds to single-stranded vRNA 
in a non-specific manner [6] with a periodicity of one NP 
molecule per every 24 bases [7, 8]. The NP contains the 
nuclear localization signal (NLS), which is essential for 
the import of vRNP complex to the nucleus where the 
mRNAs are transcribed. The newly translated NPs par-
ticipate in the protection of genomic RNA from degrada-
tion. The structure of NP is relatively conserved (less than 
11% variance) among the different influenza A strains.
Therefore, NP is an appealing target for the develop-
ment of antiviral drugs [9] and an attractive candidate 
as a component for broad-spectrum influenza vaccines 
[10, 11]. For example, it was shown that immunization 
with a plasmid DNA expressing influenza NP followed 
by boosting with adenovirus expressing NP leads to the 
induction of the protective immunity against challenge 
with highly pathogenic H5N1 influenza virus in animal 
models [12].
In addition, the NP serves as a target antigen for the 
diagnosis of influenza virus infections [13, 14]. 
Therefore, the development of efficient methods for 
recombinant NP production is an important goal. The 
expression of recombinant proteins in bacteria and/or 
eukaryotic cells is the subject of intensive studies [15, 
16]. The most prevalent approach for the acceleration of 
the recombinant protein expression is codon optimiza-
tion [17]. The successful codon-optimized expression of 
NP in E. coli and in Sf9 insect cells was shown by Huang 
et al. [18] and Yoon et al. [19], respectively. At the same 
time, as it was noted in a number of publications [16, 20, 
21], codon optimization can affect the co-translational 
protein folding, protein configuration and function. Sev-
eral recent studies proved that the use of the messen-
ger RNA containing rear codons decelerates translation 
and at the same time ensures the proper co-translational 
protein folding and consequently post-translational 
modification and function of expressed proteins [15, 
21-23]. Codon optimization can lead to disruption of 
the co-translational protein folding and consequently 
to the formation of proteins with impaired functions or 
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non-functional proteins. Konczal et al. [24] showed that 
introduction of rare codons back to the codon-optimized 
DNA sequence leads to overall slower translation, but at 
the same time to enhanced recovery of the soluble pro-
tein since it provides the proper co-translational folding 
of the recombinant protein. Codon optimization in this 
case led to enhancement of the total protein yield but to 
lower yield of the desired soluble protein. Therefore, the 
efficient expression of recombinant proteins using na-
tive DNA remains an important goal.
In this study, we showed that influenza A and B virus 
NP genes could be efficiently expressed in E.  coli with-
out resorting to codon-optimization. Both NPs produced 
by this method were monomers, were fairly well soluble, 
and possessed specific immune reactivity.
MATERIALS AND METHODS
Selection of influenza strains and the production of 
purified viral concentrates
The influenza A/Brisbane/10/2007 (H3N2) and B/Bris-
bane/46/2015 viruses were used for the production of 
recombinant NPs. These strains were obtained from the 
Smorodintsev Research Institute of Influenza (St.  Pe-
tersburg, Russia) collection. The influenza A and B vi-
ruses were grown in the allantoic cavity of 10-day old 
embryonated chicken eggs at 37℃ and 34℃, respec-
tively. Allantoic fluid was harvested in 48 h for influenza 
A and in 72  h for influenza B strain post inoculation. 
Virus-containing allantoic fluids were concentrated and 
the viruses were purified by ultracentrifugation (Beck-
man, Type 19 rotor) using sucrose density gradients [25] 
and stored at -80℃.
Construction of pET22b+NP A and pET22b+NP B 
expression plasmids
Total RNA was isolated from the corresponding purified 
viral concentrates using the Rneasy Plus Mini Kit (Qia-
gen, UK). The first strand of cDNA was synthesized using 
the RevertAid First Strand cDNA Synthesis Kit (Thermo 
Fisher Scientific, USA) with random primers. The cDNA 
corresponding to both NP genes was amplified using for-
ward primers with a NdeI restriction site and the reverse 
primers containing the XhoI restriction site (Table 1).
Table 1. Primers used for the cDNA amplification of influenza A 
and B NP genes
Primer name Sequence (5’   3’)
NPA F NdeI CATATGGCGTCCCAAGGCACCAAACG
NPA R XhoI CTCGAGATTGTCGTACTCTTCTGCATTGTCTC
NPB F NdeI CATATGTCCAACATGGATATCGA
NPB R XhoI CTCGAGATAATCGAGGTCATCAT
Polymerase chain reaction (PCR) was conducted with 
Encyclo polymerase (Evrogen, Russia) in Bio-Rad C1000 
machine (USA). PCR for the influenza B NP gene was 
challenging due to the fact that the reverse primer had 
homology with a short section in the middle of the nu-
cleotide sequence of this gene (from 299 to 306 bp). That 
led to the generation of a predominantly shorter product 
of 306 bp instead of the desired product of 1682 bp under 
a variety of conditions. This trend persisted despite the 
use of different quantities of template, extension tem-
perature gradients, and usage of different polymerases. 
Therefore, the reamplification of cDNA was not used. 
Cloning of the influenza A NP gene was straightforward.
The NP A and NP B PCR products were inserted into 
the pET22b+ commercial vector (Novagen) (Fig. 1). PCR 
products were gel-purified using the Cleanup Standard 
Kit (Evrogen, Russia) and digested by two restriction en-
zymes NdeI and XhoI (Thermo Fisher Scientific, USA). The 
pET22b+ vector was also digested by the same enzymes, 
followed by the ligation of the vector/insert mixture. 
Fig. 1. Map of the pET22b+NP expression plasmid(s).
Electrocompetent E. coli BL21(DE3) cells were trans-
formed by the ligation mix, and colonies were selected 
on LB/ampicillin (100 μg/ml) plates. After the confirma-
tion that bacteria carry the expression plasmid by PCR, 
the corresponding colonies were selected. The sequenc-
ing of the pET22b+ NP A and pET22b+ NP B constructs 
was performed using ABI PRISM 3100 Genetic Analyzer 
and their identity was confirmed by comparison to the 
original sequences of influenza A/Brisbane/10/2007 virus 
NP (PubMed accession number KJ609215.1) and influ-
enza B/Brisbane/46/2015 NP (GISAID accession number 
EPI772456) genes.
Expression and purification of the fusion proteins
Selected clones were cultured overnight on LB/ampicil-
lin plates at 37℃. The obtained cultures were dissolved 
in the pre-warmed fresh LB with ampicillin (100 μg/ml) 
to form a solution with OD600 of 0.1 and then grown in 
flasks at 37℃ with shaking until the OD600 of the solution 
reached 0.9.
Expression of the NP A and the NP B was initiated by 
the addition of IPTG to a final concentration of 0.1 mM. 
The cultures were grown for 3  h at 37℃ with 250  rpm 
shaking. Bacterial pellets were obtained from cultures by 
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centrifugation at 5000 g (Eppendorf, 5804R) for 15 min. Cell 
pellets were resuspended in 40 ml of lysis buffer (50 mM 
sodium phosphate, 500 mM sodium chloride, 20 mM imid-
azole) and 1 mM of phenylmethylsulfonyl fluoride (PMSF, 
pH 8.0) protease inhibitor. The cells were subsequently 
lysed by sonication on ice and centrifuged at 13,000 g for 
30 min to remove cell debris and insoluble proteins.
Supernatants containing soluble fractions of recom-
binant NPs (recNPs) were filtered through 0.45 μm PES 
syringe filters. A HisTrap HP one milliliter columns (GE 
Healthcare, USA) were equilibrated with 5  ml of bind-
ing buffer (50  mM sodium phosphate, 500  mM sodium 
chloride, and 20 mM imidazole, pH 8.0) at a flow rate of 
1 ml/min. Filtered supernatants were loaded on the col-
umns at the same flow rate. Then columns were washed 
with 20 ml of binding buffer in order to remove unbound 
material followed by elution with 10 ml of elution buf-
fer (50 mM sodium phosphate, 500 mM sodium chloride, 
and 500  mM imidazole, pH 7.8) at the same flow rate. 
Protein-containing fractions were collected, combined, 
and passed through a ten milliliter BioScale Mini P-6 
desalting cartridge (Bio-Rad, USA), preliminary equili-
brated with PBS buffer, at a flow rate of 5 ml/min. Protein 
concentrations were determined by Lowry assay, and the 
purity of the recNPs were determined by SDS-PAGE and 
densitometry. 
HPLC purification of recNP was performed using Akta 
Pure system with the Superdex 200 Increase 10/300 GL 
column (GE Healthcare) for size-exclusion chromatogra-
phy. Column was equilibrated with 75 ml of HPLC buffer 
(150 mM NaCl, 30 mM Na3PO4, pH 7.8) at 0.5 ml/min flow 
rate. The injection volume of a sample was 100 μl, elution 
volume was 30 ml. 
Calibration was done using a series of proteins with 
known molecular weight (MW). Using the obtained 
chromatographic data MW for purified recNP A was de-
termined as 57 kDa, that matches the predicted MW of 
recNP A monomeric form. The chromatogram is shown 
in Fig. 2.
SDS-PAGE assay
Samples (cell lysates, elution fractions with purified 
protein, and negative control cell lysates) were mixed 
with 4x loading buffer containing reducing agent 
β-mercaptoethanol and incubated at 95℃ for 10  min. 
Then, the mixtures were separated by SDS-PAGE on the 
12% separating gel according to the standard procedure 
and subsequently stained with Coomassie blue R-250. 
Western blot analysis
Purified proteins were analyzed by Western blot using an-
tibodies to His tag (Qiagen AntiHis5, #34660) and mono-
clonal antibodies 4H1 generated to the NP of influenza 
virus A/Brisbane/10/2007 as well as antibodies 1B12 gen-
erated to the NP of B/Brisbane/46/2015 virus obtained in 
the Smorodintsev Research Institute of Influenza (St. Pe-
tersburg, Russia). Proteins were transferred to nitrocellu-
lose membranes using the Bio-Rad Trans Blot Turbo sys-
tem. Then, the membrane was blocked with non-fat dried 
milk (NFDM) in PBS buffer containing 0.05% Tween 20 
(PBST) for 1 h and incubated with primary antibody so-
lutions (antibodies to His tag or monoclonal antibodies 
4H1 and 1B12) in 4% NFDM (Sigma Aldrich) for 2 h fol-
lowing by incubation with secondary antibodies (GAM, 
Sigma Aldrich, #A3682) for 1 h in PBST buffer.
RESULTS AND DISCUSSION
The NP A and NP B PCR products of influenza A/Bris-
bane/10/2007 (H3N2) and B/Brisbane/46/2015, respec-
tively, were inserted into the pET22b+ commercial vec-
tor (Novagen). The expression vectors pET22b+NP A and 
pET22b+NP B were designed to produce recNP A and 
recNP B proteins with a c-terminal 6xHis tag as shown 
in Fig. 1. The NP A (1496 bp) and NP B (1682 bp) coding 
sequences were amplified from cDNAs transcribed from 
the corresponding viral RNAs using the primers shown 
in the Table 1. As was mentioned hereinabove, the am-
plification of influenza B NP was more problematic due 
to a partial homology of the reverse primer to an internal 
region of the gene (from 299 to 306  bp) leading to the 
amplification of a shorter product. Therefore, the cloning 
of the NP of influenza B virus was performed after one 
PCR round. The sequencing of the plasmids from the cor-
responding colonies showed the presence of full-length 
inserts identical to the original sequences. 
The pET22b+NP A and pET22b+NP B plasmids were 
transformed into E.  coli BL21(DE3). In the standard in-
duction procedure, cultures were grown for 3 h at 37℃ 
with shaking (250 rpm) in the presence of IPTG (inductor) 
at a final concentration of 0.1 mM. In order to maximize 
Fig. 2. The HPLC chromatogram of purified recNP A verses a chro-
matogram of the mixture of molecular mass standards.  
1 – ferritin (440 kDa), 2 – ovalbumin (44 kDa), 3 – RNase A 
(13.5 kDa), 4 – aprotinin (6.5 kDa), NP – purified recNP A.
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the yield of soluble NPs, different experimental conditions 
were screened: various IPTG concentrations (0.05, 0.1, 
and 0.5  mM) and incubation temperatures (23℃, 32℃, 
and 37℃). No difference in the protein expression level at 
different experimental conditions was observed. There-
fore, the transformed E. coli were grown at 37℃ with the 
addition of IPTG up to 0.1 mM until the OD600 of culture 
reached the value of 0.9. Then, the cells were incubated 
for an additional 3 h. Bacterial cell pellets were obtained 
by centrifugation at 5,000 g for 15 min (Eppendorf, 5804R), 
resuspended in lysis buffer, and lysed by sonification using 
the homogenizer (MSE Soniprep 150, UK).
Supernatants containing soluble fractions of recNPs 
were purified using Ni-NTA columns and then the prod-
ucts were eluted with high imidazole buffer. Total lysates, 
fractions, and purified proteins were analyzed by SDS-
PAGE. This analysis showed the presence of bands of ap-
proximately 57 kDa and 62 kDa (Fig. 3) that correlate well 
with the predicted molecular weight of the recNP fusion 
proteins of influenza A and B viruses, respectively. After 
Ni2+ affinity chromatography, the purity of both proteins 
was above 95%. From 1  liter of the corresponding cul-
tures, 15 mg of NP A and 5 mg of NP B were isolated.
Western blot analysis indicated that purified recNP A 
and recNP B reacted well with the monoclonal anti bodies 
obtained to influenza A/Brisbane/10/2007 and B/Bris-
bane/46/2015 viruses, respectively. Both proteins also re-
acted well with anti-His tag antibodies (Qiagen AntiHis5, 
#34660) (Fig. 4). 
The codon optimization of DNA sequences is widely 
used in order to increase the expression level of target 
proteins. A synonymous codon substitutions – substi-
tutions of codons that are translated slower by faster 
translated codons – can significantly increase the rate of 
translation of the desired protein [26]. However, it was 
shown that this procedure can influence the protein fold-
ing and stability and can interfere with post-translation-
al protein modification [23, 27]. Some slower translated 
Fig. 3. SDS-PAGE of E. coli lysates and purified NPs.
A. NP of influenza A virus: C – negative control, containing E. coli BL21(DE3) with pET22b+, 1- total lysate, 2 – soluble fraction, 3 – pellet, 
4 – purified recombinant NP, M – molecular marker; B. NP of influenza B virus: C – negative control, containing E. coli BL21(DE3) with 
pET22b+, 1 – total lysate, 2 – soluble fraction, 3 – pellet, and 4 – purified recombinant NP, M – molecular marker.
Fig. 4. Western blot analysis of purified recombinant NPs. 
A. Staining with antibodies to 6xHis tag. B. Staining with mouse monoclonal antibodies 4H1 specific to NP of A/Brisbane/10/2007 and 1B12 
specific to NP of influenza B/Brisbane/46/2015 virus. M – molecular marker, 1 – NP of A/Brisbane/10/2007, 2 – NP of B/Brisbane/46/2015 
virus.
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codons were shown to have advantages for conserving 
the exact protein structure especially if they encode the 
amino acids that are located at the key positions of the 
protein sequence because mutation at these positions 
would drastically influence the protein properties [28, 
29]. Therefore, codon optimization leads not only to the 
regulation of the protein expression level, but also can 
influence the structure and function of the expressed 
proteins. In summary, we showed that influenza A and B 
heterologous NPs can be successfully expressed in E. coli 
using original sequences. Both expressed nucleoproteins 
demonstrated good immune reactivity with specific an-
tibodies.
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